The U.S. Food and Drug Administration (FDA) has approved a groundbreaking new treatment option for adults with newly diagnosed acute myeloid leukemia (AML). The approval allows the use of Inqovi in combination with venetoclax for patients aged 75 and older or those who cannot undergo intensive induction chemotherapy. This marks the first fully oral combination treatment approved for this AML patient population.
The announcement from Taiho Oncology and Taiho Pharmaceutical represents an important advancement in leukemia care. Traditionally, many AML patients who are not eligible for aggressive chemotherapy have required injectable or infusion-based treatments that involve frequent hospital or clinic visits. The new all oral regimen may offer greater convenience and potentially reduce the burden associated with treatment administration.
Inqovi is an oral fixed dose combination medicine containing decitabine and cedazuridine. Decitabine is a hypomethylating agent that helps slow or stop the growth of cancer cells. Cedazuridine helps improve the body’s absorption of decitabine when taken orally.
The medication was previously approved in the United States and Canada for treating myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The latest FDA approval expands its use to newly diagnosed AML patients when combined with venetoclax.
Venetoclax is a targeted therapy that works by blocking the BCL-2 protein, which helps cancer cells survive. Combining venetoclax with hypomethylating agents has become an increasingly important strategy in AML treatment.
Acute myeloid leukemia is a rapidly progressing cancer affecting the blood and bone marrow. According to the American Cancer Society, more than 22,000 people in the United States are expected to be diagnosed with AML in 2026. Many of these patients are older adults or individuals with underlying health conditions that make intensive chemotherapy too risky.
Until now, patients often relied on intravenous hypomethylating agent based therapies that required regular hospital or infusion center visits. The approval of an all oral regimen introduces a potentially more manageable treatment option for eligible patients.
According to Taiho Oncology President and CEO Peter Melnyk, the approval represents a significant milestone for AML patients who are not candidates for intensive induction chemotherapy. The company emphasized its commitment to expanding patient focused treatment options in hematologic cancers.
The FDA approval was supported by findings from the Phase 2 ASCERTAIN-V clinical trial, which evaluated Inqovi plus venetoclax in adults with newly diagnosed AML who were ineligible for intensive induction chemotherapy.
The trial demonstrated encouraging remission outcomes:
Importantly, researchers reported no new safety concerns during the study.
These findings suggest that the oral combination therapy may provide meaningful clinical benefits while maintaining a manageable safety profile for many patients.
One of the most important aspects of this approval is convenience. Oral cancer treatments can reduce the need for repeated hospital visits and long infusion appointments.
Potential advantages may include:
For older AML patients who may already face mobility or health challenges, an oral regimen could represent a significant improvement in daily cancer management.
While the approval is promising, Inqovi plus venetoclax also carries important safety warnings.
The prescribing information highlights risks including:
In clinical studies, some patients experienced severe or fatal complications related to infections and low blood cell counts. Healthcare providers are advised to closely monitor blood counts before and during treatment.
Patients should immediately report symptoms such as fever, shortness of breath, unusual bleeding, fatigue, or signs of infection.
Inqovi combines two active ingredients designed to work together effectively in oral form.
Decitabine interferes with abnormal DNA methylation patterns associated with cancer cell growth. Cedazuridine blocks the breakdown of decitabine in the digestive system and liver, helping maintain therapeutic drug levels similar to intravenous decitabine.
This combination allows patients to receive hypomethylating therapy orally rather than through IV administration.
The FDA approval reflects a broader trend in oncology toward oral therapies that can be administered at home. Advances in targeted medicine and supportive care have accelerated the development of oral treatment options across multiple cancer types.
For AML specifically, treatment innovation has expanded significantly in recent years. Historically, many AML therapies were limited to intensive hospital based chemotherapy. Today, targeted therapies and lower intensity regimens are providing additional choices for patients who may not tolerate aggressive treatment.
Experts believe oral regimens may continue to reshape how blood cancers are managed, particularly among elderly and medically vulnerable populations.
The approval of Inqovi plus venetoclax may encourage additional research into fully oral leukemia treatment strategies. Researchers continue to investigate combination therapies aimed at improving survival outcomes while minimizing treatment burden.
Taiho Oncology also maintains an active pipeline of oral anticancer therapies for both hematologic malignancies and solid tumors.
As AML treatment continues evolving, personalized care approaches are becoming increasingly important. Physicians now have more flexibility to tailor therapy based on patient age, overall health, genetic mutations, and treatment goals.
The FDA approval of Inqovi in combination with venetoclax marks a major advancement for adults with newly diagnosed AML who cannot undergo intensive chemotherapy. As the first fully oral treatment regimen approved for this patient group, the therapy offers a new alternative that may reduce clinic dependence and improve convenience for patients and caregivers.
Although the regimen carries serious safety risks that require careful monitoring, the clinical trial results demonstrate promising remission outcomes for a difficult to treat population. The approval also highlights the ongoing transformation of leukemia care through oral targeted therapies and patient centered treatment innovation.
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Patients should consult qualified healthcare professionals regarding any medical condition or treatment decisions. Do not start or stop any medication without medical supervision.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.